Viridian Therapeutics
Logotype for Viridian Therapeutics Inc

Viridian Therapeutics (VRDN) investor relations material

Viridian Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Viridian Therapeutics Inc
Jefferies Global Healthcare Conference summary16 Nov, 2026

LUMVOA launch

  • First-quarter launch revenue was $24.7 million, with >100 patients on therapy as of Sept. 30; management said execution exceeded expectations.

  • Most patients had a proptosis response after one infusion; chronic TED patients showed complete diplopia resolution, and the planned course is five infusions vs. TEPEZZA’s eight.

  • Management expects a fast path to peak in a new-start market, but said the actual timeline remains to be seen; launch is still early.

Commercial access and execution

  • Formal policy coverage reached 30% of covered lives by the end of September; other patients can pursue access through medical exceptions.

  • Payers indicated parity pricing could support parity coverage; TEPEZZA reached 85% of covered lives in nearly five years, while management targets critical mass within 6–9 months of launch.

  • More than 95% of ~2,000 core prescribers had been engaged within four weeks of launch; the field team was active with physicians within 24 hours of launch.

  • A permanent J-code takes effect Jan. 1; management expects limited overall impact, with potential help for smaller infusion centers.

SubQ elegrobart

  • After two positive Phase III readouts earlier in 2026, the BLA for subQ IGF-1R is planned for Q1 2027.

  • Development plans include Q4-weekly and Q8-weekly regimens; the Q8-weekly course would involve three administrations at day 1, week 8 and week 16.

  • Management expects subQ convenience to expand the market, particularly by reaching patients deterred by infusions; IV is expected to remain an option for controlled settings and severe, sight-threatening disease.

  • Q4-weekly data showed diplopia response and resolution; Q8-weekly dosing may suit patients whose primary concerns are proptosis or pain.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Viridian Therapeutics earnings date

Logotype for Viridian Therapeutics Inc
Q4 202626 Feb, 2027
Viridian Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Viridian Therapeutics earnings date

Logotype for Viridian Therapeutics Inc
Q4 202626 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Viridian Therapeutics Inc. is a biotechnology company focused on developing treatments for patients with serious diseases, particularly those related to rare and underserved conditions. The company’s primary area of research includes therapies for thyroid eye disease (TED) and other autoimmune and inflammatory diseases. Viridian Therapeutics employs innovative biologics and small-molecule technologies to address unmet medical needs and improve patient outcomes through targeted therapeutic approaches. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.